Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 19, Issue 19, Pages 1694-1711Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026619666190619115735
Keywords
Hybrids; Framework combination; Alzheimer's disease; Parasitic disease; Multitarget drug discovery; Fragment-based drug discovery
Categories
Funding
- International Cooperation Program CAPES/PDSE at the University of Bologna, Italy [88881.187586/2018-01]
Ask authors/readers for more resources
Molecular hybridization is a well-exploited medicinal chemistry strategy that aims to combine two molecules (or parts of them) in a new, single chemical entity. Recently, it has been recognized as an effective approach to design ligands able to modulate multiple targets of interest. Hybrid compounds can be obtained by linking (presence of a linker) or framework integration (merging or fusing) strategies. Although very promising to combat the multifactorial nature of complex diseases, the development of molecular hybrids faces the critical issues of selecting the right target combination and the achievement of a balanced activity towards them, while maintaining drug-like-properties. In this review, we present recent case histories from our own research group that demonstrate why and how molecular hybridization can be carried out to address the challenges of multitarget drug discovery in two therapeutic areas that are Alzheimer's and parasitic diseases. Selected examples spanning from linker-to fragment-based hybrids will allow to discuss issues and consequences relevant to drug design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available